Charles River Laboratorie... (CRL)
Charles River Laboratories International Statistics
Share Statistics
Charles River Laboratories International has 51.14M shares outstanding. The number of shares has increased by -0.42% in one year.
| Shares Outstanding | 51.14M |
| Shares Change (YoY) | -0.42% |
| Shares Change (QoQ) | -0.96% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 50.57M |
| Failed to Deliver (FTD) Shares | 1.76K |
| FTD / Avg. Volume | 0.15% |
Short Selling Information
The latest short interest is 2.16M, so 4.22% of the outstanding shares have been sold short.
| Short Interest | 2.16M |
| Short % of Shares Out | 4.22% |
| Short % of Float | 4.26% |
| Short Ratio (days to cover) | 3.14 |
Valuation Ratios
The PE ratio is 429.84 and the forward PE ratio is 16.58. Charles River Laboratories International's PEG ratio is -4.63.
| PE Ratio | 429.84 |
| Forward PE | 16.58 |
| PS Ratio | 2.36 |
| Forward PS | 1.7 |
| PB Ratio | 2.76 |
| P/FCF Ratio | 19.03 |
| PEG Ratio | -4.63 |
Enterprise Valuation
Charles River Laboratories International Inc. has an Enterprise Value (EV) of 14.9B.
| EV / Earnings | 671.07 |
| EV / Sales | 3.68 |
| EV / EBITDA | 25.64 |
| EV / EBIT | 65.54 |
| EV / FCF | 29.7 |
Financial Position
The company has a current ratio of 1.41, with a Debt / Equity ratio of 0.79.
| Current Ratio | 1.41 |
| Quick Ratio | 1.13 |
| Debt / Equity | 0.79 |
| Total Debt / Capitalization | 44.04 |
| Cash Flow / Debt | 0.27 |
| Interest Coverage | 1.8 |
Financial Efficiency
Return on equity (ROE) is 0.01% and return on capital (ROIC) is 0.99%.
| Return on Equity (ROE) | 0.01% |
| Return on Assets (ROA) | 0% |
| Return on Capital (ROIC) | 0.99% |
| Revenue Per Employee | $216,576.95 |
| Profits Per Employee | $1,187.33 |
| Employee Count | 18,700 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 9.76 |
Taxes
| Income Tax | 67.82M |
| Effective Tax Rate | 0.73 |
Stock Price Statistics
The stock price has increased by -42.57% in the last 52 weeks. The beta is 1.45, so Charles River Laboratories International's price volatility has been higher than the market average.
| Beta | 1.45 |
| 52-Week Price Change | -42.57% |
| 50-Day Moving Average | 164.9 |
| 200-Day Moving Average | 191.3 |
| Relative Strength Index (RSI) | 37.28 |
| Average Volume (20 Days) | 1.15M |
Income Statement
In the last 12 months, Charles River Laboratories International had revenue of 4.05B and earned 22.2M in profits. Earnings per share was 0.67.
| Revenue | 4.05B |
| Gross Profit | 1.33B |
| Operating Income | 227.35M |
| Net Income | 22.2M |
| EBITDA | 581.14M |
| EBIT | 227.35M |
| Earnings Per Share (EPS) | 0.67 |
Balance Sheet
The company has 194.61M in cash and 2.72B in debt, giving a net cash position of -2.53B.
| Cash & Cash Equivalents | 194.61M |
| Total Debt | 2.72B |
| Net Cash | -2.53B |
| Retained Earnings | 1.81B |
| Total Assets | 7.53B |
| Working Capital | 408.97M |
Cash Flow
In the last 12 months, operating cash flow was 734.58M and capital expenditures -232.97M, giving a free cash flow of 501.61M.
| Operating Cash Flow | 734.58M |
| Capital Expenditures | -232.97M |
| Free Cash Flow | 501.61M |
| FCF Per Share | 9.78 |
Margins
Gross margin is 32.88%, with operating and profit margins of 5.61% and 0.55%.
| Gross Margin | 32.88% |
| Operating Margin | 5.61% |
| Pretax Margin | 2.3% |
| Profit Margin | 0.55% |
| EBITDA Margin | 14.35% |
| EBIT Margin | 5.61% |
| FCF Margin | 12.39% |
Dividends & Yields
CRL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 0.43% |
| FCF Yield | 6.3% |
Analyst Forecast
The average price target for CRL is $179.5, which is 15.4% higher than the current price. The consensus rating is "Hold".
| Price Target | $179.5 |
| Price Target Difference | 15.4% |
| Analyst Consensus | Hold |
| Analyst Count | 14 |
Scores
| Altman Z-Score | 2.24 |
| Piotroski F-Score | 6 |